Calcitonin

P. M. Sexton, D. M. Findlay, T. J. Martin

Research output: Contribution to journalArticleResearchpeer-review

160 Citations (Scopus)

Abstract

The peptide calcitonin (CT) was initially discovered in 1962 as a novel hypocalcemic hormone. This hypocalcemic response was principally due to a potent inhibitory action of CT on osteoclast mediated bone resorption and it is this action which underlies its widespread clinical use for the treatment of bone disorders, including Paget's disease, osteoporosis and hypercalcemia of malignancy. In this article we review the basic physiology of CT action, structure-function studies on CT peptides, cloning of CT receptors and the identification of isoforms of the receptor derived from alterative splicing of the receptor mRNA. We also review the state of understanding on CT receptor mediated signaling and receptor regulation, along with developing concepts of how CT peptides interact with the receptor, including how the receptors may interact with receptor activity modifying proteins to produce novel phenotypes. Finally, current therapeutic use is reviewed, and the potential for expanded use that may come with advances in delivery of peptides or CT mimetics.

Original languageEnglish
Pages (from-to)1067-1093
Number of pages27
JournalCurrent Medicinal Chemistry
Volume6
Issue number11
Publication statusPublished - 3 Nov 1999
Externally publishedYes

Cite this

Sexton, P. M., Findlay, D. M., & Martin, T. J. (1999). Calcitonin. Current Medicinal Chemistry, 6(11), 1067-1093.
Sexton, P. M. ; Findlay, D. M. ; Martin, T. J. / Calcitonin. In: Current Medicinal Chemistry. 1999 ; Vol. 6, No. 11. pp. 1067-1093.
@article{82458e33b36842f387a4487e9f68fbd1,
title = "Calcitonin",
abstract = "The peptide calcitonin (CT) was initially discovered in 1962 as a novel hypocalcemic hormone. This hypocalcemic response was principally due to a potent inhibitory action of CT on osteoclast mediated bone resorption and it is this action which underlies its widespread clinical use for the treatment of bone disorders, including Paget's disease, osteoporosis and hypercalcemia of malignancy. In this article we review the basic physiology of CT action, structure-function studies on CT peptides, cloning of CT receptors and the identification of isoforms of the receptor derived from alterative splicing of the receptor mRNA. We also review the state of understanding on CT receptor mediated signaling and receptor regulation, along with developing concepts of how CT peptides interact with the receptor, including how the receptors may interact with receptor activity modifying proteins to produce novel phenotypes. Finally, current therapeutic use is reviewed, and the potential for expanded use that may come with advances in delivery of peptides or CT mimetics.",
author = "Sexton, {P. M.} and Findlay, {D. M.} and Martin, {T. J.}",
year = "1999",
month = "11",
day = "3",
language = "English",
volume = "6",
pages = "1067--1093",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers",
number = "11",

}

Sexton, PM, Findlay, DM & Martin, TJ 1999, 'Calcitonin', Current Medicinal Chemistry, vol. 6, no. 11, pp. 1067-1093.

Calcitonin. / Sexton, P. M.; Findlay, D. M.; Martin, T. J.

In: Current Medicinal Chemistry, Vol. 6, No. 11, 03.11.1999, p. 1067-1093.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Calcitonin

AU - Sexton, P. M.

AU - Findlay, D. M.

AU - Martin, T. J.

PY - 1999/11/3

Y1 - 1999/11/3

N2 - The peptide calcitonin (CT) was initially discovered in 1962 as a novel hypocalcemic hormone. This hypocalcemic response was principally due to a potent inhibitory action of CT on osteoclast mediated bone resorption and it is this action which underlies its widespread clinical use for the treatment of bone disorders, including Paget's disease, osteoporosis and hypercalcemia of malignancy. In this article we review the basic physiology of CT action, structure-function studies on CT peptides, cloning of CT receptors and the identification of isoforms of the receptor derived from alterative splicing of the receptor mRNA. We also review the state of understanding on CT receptor mediated signaling and receptor regulation, along with developing concepts of how CT peptides interact with the receptor, including how the receptors may interact with receptor activity modifying proteins to produce novel phenotypes. Finally, current therapeutic use is reviewed, and the potential for expanded use that may come with advances in delivery of peptides or CT mimetics.

AB - The peptide calcitonin (CT) was initially discovered in 1962 as a novel hypocalcemic hormone. This hypocalcemic response was principally due to a potent inhibitory action of CT on osteoclast mediated bone resorption and it is this action which underlies its widespread clinical use for the treatment of bone disorders, including Paget's disease, osteoporosis and hypercalcemia of malignancy. In this article we review the basic physiology of CT action, structure-function studies on CT peptides, cloning of CT receptors and the identification of isoforms of the receptor derived from alterative splicing of the receptor mRNA. We also review the state of understanding on CT receptor mediated signaling and receptor regulation, along with developing concepts of how CT peptides interact with the receptor, including how the receptors may interact with receptor activity modifying proteins to produce novel phenotypes. Finally, current therapeutic use is reviewed, and the potential for expanded use that may come with advances in delivery of peptides or CT mimetics.

UR - http://www.scopus.com/inward/record.url?scp=0032726789&partnerID=8YFLogxK

M3 - Article

C2 - 10519914

AN - SCOPUS:0032726789

VL - 6

SP - 1067

EP - 1093

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 11

ER -

Sexton PM, Findlay DM, Martin TJ. Calcitonin. Current Medicinal Chemistry. 1999 Nov 3;6(11):1067-1093.